How Novo Nordisk lost its lead in the weight loss race
Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors
Related reading
Weight-loss drugs and Mars bars: Novo Nordisk’s comeback bid
The maker of Wegovy and Ozempic wants to learn lessons from consumer groups to crack the US market
Triple dose of Novo Nordisk drug delivers 19% weight loss in trials
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
Novo Nordisk loses further ground in obesity market
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Pharma just ‘scratching the surface’ of weight-loss drug market
Novo Nordisk chief estimates industry reaching only 15% of potential customers at most
Battle for weight-loss supremacy shifts from jabs to pills
Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly
Novo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs…
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill